Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

First insights in real-world effectiveness of erenumab in chronic migraine patients with high burden of disease in Germany from the NTD headache and migraine registry
Headache
P11 - Poster Session 11 (8:00 AM-9:00 AM)
7-006

Evaluation of patient characteristics and clinical effectiveness of erenumab in real-world care within the framework of German regulatory guidelines

German regulatory guidelines require 5 (episodic migraine) or 6 (chronic migraine) failed or contraindicated prophylactic treatments in migraine patients before erenumab is covered by public health insurances. Clinical effectiveness of erenumab in a chronic headache population with a high burden of disease und comorbidities is unknown.
The headache registry of the German NeuroTransData (NTD) doctors network was started in Oktober 2017 capturing demographics, headache days, use and effect of acute medication and patient-related outcomes via standardized webbased data entry and NTD patient smartphone app. Diagnostic assessment is based on ICHD-3 criteria.
Currently (09 22 19), 3607 migraine patients are documented (83.3% females). 4.3% use non-drug prophylaxis, 24.3% established prophylaxis drugs and 5.5% CGRP-effective prophylaxis with erenumab and others. Erenumab was initiated with 70mg in 96% of patients, with 28% being switched to 140mg within 7months. 8.3% were discontinued due to lack of efficacy, 2.2% due to adverse events within the first 10months of follow-up. In 75% erenumab was the only prophylaxis, in 25% in combiation with others. More than 50% of patients achieved at least a 50% reduction of migraine days within 3 months. Response was independent of the number of unsuccessful previous treatments.

The results from the NTD headache registry provide first insights into the effectiveness of erenumab in real-world care prescribed within the guidelines for economic use in Germany. Erenumab is very well tolerated and achieves a responder rate >50% in patients with chronic high burden of disease and a history of up to 6 failed or contrainidicated prophylactic treatments. The NTD headache registry will enable more deeper insights into the care of migraine patients and treatment effectiveness as more data accumulate over time.

Authors/Disclosures
Stefan Braune (Gemeinschaftspraxis)
PRESENTER 		Stefan Braune has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuroTransData. Stefan Braune has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Stefan Braune has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for NeuroTransData.
No disclosure on file
Monika Koerwer, MD (Neurocentrum) No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Arnfin Bergmann Dr. Bergmann has nothing to disclose.